MRNA Jan 2025 110.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:08PM EDT
Loading interactive chart…
- Zacks
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
- Simply Wall St.
Moderna (NASDAQ:MRNA) shareholders are still up 857% over 5 years despite pulling back 6.1% in the past week
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
- Investor's Business Daily
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Moderna stock is trading sideways despite a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
© 2024 Yahoo. All rights reserved.